Keyphrases
Tyrosine Kinase Inhibitor
100%
Practical Management
100%
Chronic Myeloid Leukemia
100%
Imatinib
100%
Toxicity Management
100%
Abl Kinase
66%
Adverse Effects
33%
BCR-ABL
33%
Clinical Management
33%
Clinical Response
33%
Adverse Events
33%
Therapeutic Approaches
33%
Patient's Will
33%
Inhibitory Activity
33%
Dasatinib
33%
Kinase Domain
33%
Nilotinib
33%
Imatinib Resistance
33%
Complete Cytogenetic Response
33%
Treatment Interruption
33%
Second-generation TKI
33%
Tyrosine Kinase Inhibitor Therapy
33%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
100%
Imatinib
100%
Chronic Myelogenous Leukemia
100%
Adverse Event
66%
Abelson Kinase
66%
Disease
33%
Clinical Management
33%
Dasatinib
33%
Treatment Interruption
33%
Nilotinib
33%
Imatinib Resistance
33%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Chronic Myeloid Leukemia
100%
Imatinib
100%
Adverse Event
50%
Abelson Kinase
50%
Disease
25%
Dasatinib
25%
Nilotinib
25%